Handelsavisen
prelaunch
Companies ›Healthcare ›191420.KQ
19
191420.KQ — KOSDAQ Pharmaceuticals

Tego Science Inc

$7 880,00
Open in Charts → Attach watcher ⌖
— —
KRW
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
63,1B KRW
P/E
—
EV / Rev
14,6x
Div yield
—
Op margin
-66,6 %
ROE
-1,4 %
Net margin
-51,6 %
Debt / equity
0,04
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Tego Science Inc is a biotechnology company focused on pharmaceuticals and medical research, generating revenue primarily through the development and commercialization of biopharmaceutical products.

Business. Tego Science Inc is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm is headquartered in South Korea and is primarily listed on the KOSDAQ under the ticker symbol 191420.KQ. Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
-1,4 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 191420.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 191420.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Tego Science Inc is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm is headquartered in South Korea and is primarily listed on the KOSDAQ under the ticker symbol 191420.KQ. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    Tego Science Inc has a strong liquidity position, with a current ratio of 12.37, indicating that the company holds significantly more current assets than current liabilities. The company's cash and equivalents amount to KRW 1,994,340,370, which is a substantial portion of its total assets of KRW 48,279,019,040. However, the company's free cash flow is negative at KRW -668,773,950, suggesting that it is currently investing more in capital expenditures than it is generating in operating cash flow.

    The company's profitability metrics are weak, with a net loss of KRW -657,589,450 and an operating loss of KRW -848,298,530. The return on equity (ROE) is -1.43%, and the return on assets (ROA) is -1.36%, both of which are significantly below the industry median for biotechnology firms. The gross profit margin is 66.47%, which is relatively high, but the operating margin is -66.63%, indicating that the company is not effectively managing its operating expenses.

    Tego Science Inc's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. The company's revenue of KRW 1,273,632,170 is derived from its core pharmaceutical and medical research activities. There is no indication of significant revenue diversification across different product lines or geographic regions.

    The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. The negative operating and net income suggest that the company is not currently generating profits, and the free cash flow is negative, indicating that the company is investing in its operations. The capital expenditure of KRW -137,598,240 suggests that the company is investing in its infrastructure and research capabilities.

    The risk assessment for Tego Science Inc indicates a low level of liquidity and dilution risk. The company's debt-to-equity ratio is 0.04, which is relatively low, and there are no immediate filing-based liquidity or dilution flags. The company's valuation metrics, including a price-to-book ratio of 1.9 and an enterprise value-to-revenue ratio of 67.91, suggest that the company is currently undervalued relative to its revenue.

    Recent events and filings do not indicate any significant changes in the company's financial position or strategic direction. The company's financial statements do not mention any recent acquisitions, partnerships, or regulatory changes that could impact its future performance. The company's focus remains on its core pharmaceutical and medical research activities.

    Key takeaways
    • Tego Science Inc has a strong liquidity position with a current ratio of 12.37.
    • The company is currently unprofitable, with a net loss of KRW -657,589,450 and an operating loss of KRW -848,298,530.
    • The company's revenue is concentrated in a single business segment, with no geographic diversification provided.
    • The company's valuation metrics suggest it is undervalued relative to its revenue, with a price-to-book ratio of 1.9 and an enterprise value-to-revenue ratio of 67.91.
    • The company has a low debt-to-equity ratio of 0.04, indicating a conservative capital structure.
    • The company is investing in its operations, with a capital expenditure of KRW -137,598,240.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 2

    The company maintains a low debt-to-equity ratio of 0.04, which is above the pharmaceutical cohort median of 0.18.

    Dilution and liquidity risks are assessed as low, suggesting stable capital structure and market trading conditions.

    BEAR CASE · 1

    The company faces high credit risk, indicating significant concerns regarding its ability to meet financial obligations.

    In focus — financials by report

    Valuation FY

    Market price
    $7 880,00
    Market cap
    $86.87B
    Enterprise valueⓘ
    $86.49B
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    14.6x
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    1797.2x
    P / Bⓘ
    1.9x
    P / Tangible bookⓘ
    1.9x
    Tangible book
    $45.83B
    Net cashⓘ
    $377.2M
    Current ratioⓘ
    12.4
    Debt / equityⓘ
    0.0
    ROAⓘ
    -1.4%
    ROEⓘ
    -1.4%
    Cash conversionⓘ
    -7.0%
    CapEx / revenueⓘ
    -10.8%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-66,6 %Bottom quartile
    Net Margin-51,6 %Bottom quartile
    ROE-1,4 %Below median
    Capex / Rev-10,8 %Below median
    D/E0,04Above median
    Cash Conv-0,07Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • Tego Science Inc Market data — financials · 2026-05-26

    Ownership & reference

    Leadership

    • Se Hwa JeonPresident, Chief Executive Officer, Director

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    191420.KQCanonical
    KOSDAQ · KRW

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage